Kezar Life Sciences, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported net loss was USD 24.31 million compared to USD 16.19 million a year ago. Basic loss per share from continuing operations was USD 0.34 compared to USD 0.25 a year ago.
For the six months, net loss was USD 46.51 million compared to USD 32.21 million a year ago. Basic loss per share from continuing operations was USD 0.64 compared to USD 0.52 a year ago.